<DOC>
	<DOCNO>NCT02444143</DOCNO>
	<brief_summary>Tacrolimus extend release ( Astagraf ) recently approve FDA day dose regimen . This formulation potential improve compliance . Current dose recommendation extend release formulation renal transplant 0.15 mg/kg/day administer daily morning . There specification appropriate dose obese patient whether use actual , ideal adjust weight . It advantageous understand pharmacokinetics medication obese determine appropriate dose regimen . In study , obese patient randomize receive tacrolimus extend release 0.15 mg/kg/day base either ideal body weight ( IBW ) adjust body weight ( aBW ) .</brief_summary>
	<brief_title>A Pharmacokinetic Analysis Tacrolimus ER Dosing Obese Kidney Transplant Recipients</brief_title>
	<detailed_description>Tacrolimus exhibit significant inter- intra-individual variability absorption metabolism . Because variability , standard dose accurate predictor drug exposure . In clinical use , tacrolimus whole blood trough concentration measure ensure efficacy safety . Furthermore , relatively low bioavailability tacrolimus think result combination poor water-solubility , pre-systemic metabolism tacrolimus gastrointestinal tract activity P-glycoprotein efflux pump find enterocytes GI tract . Tacrolimus extensively metabolize cytochrome P-450 system ( CYP3A ) . The plasma protein bind tacrolimus approximately 99 % . Tacrolimus bound mainly albumin alpha-1-acid glycoprotein . The distribution tacrolimus blood plasma depend several factor include hematocrit , temperature time plasma separation , drug concentration , plasma protein concentration . Pharmacodynamic study reveal , depend time follow transplantation , maintain whole blood trough level 5 20 ng/mL provide adequate protection acute rejection limit occurrence adverse event . The management tacrolimus blood level complicate variable intra- inter-patient absorption , interaction food concomitant medication , relatively low bioavailability tacrolimus Prograf formulation ( 17 ± 10 % adult kidney transplant patient ) . Previous study examine immunosuppressant show drug level immediate post-transplant period major determinant subsequent acute cellular rejection . It known tacrolimus ( TAC ) &lt; 10 ng/mL associate increase rate acute cellular rejection one month post-transplant . There controversy regard appropriate dosing weight use immunosuppressant ( IS ) . Weights use range ideal body weight ( IBW ) total body weight ( TBW ) depend institution drug dose . This become particularly important obese population significant difference IBW TBW . Our institution always use IBW dosing IS due concern nephrotoxicity initial high blood level tacrolimus . The concern obese patient investigator underdosing population could high risk rejection due high circulate concentration pro-inflammatory cytokine . The introduction novel use robotic transplantation procedure institution patient population lead increase number transplant obese recipient ; therefore , investigator decide re-evaluate dosing protocol . Data internal study UIC show use IBW tacrolimus dose sufficient obese population ( body mass index [ BMI ] ≥30 ) . The dose use month 3 closer 0.1 mg/kg/day total body weight utilized . However , use adjust body weight ( aBW ) common medication dose obese patient . Adjusted body weight calculate TBW great 30 % calculated IBW . aBW = IBW + 0.4 ( TBW - IBW ) . There limited data available support use either IBW aBW dose tacrolimus within obese patient patient typically exclude clinical trial , particularly pharmacokinetic trial . In addition , literature available compare two dose weight determine lead therapeutic concentration effectively . Summary Present Study Tacrolimus extend release ( Astagraf ) recently approve FDA day dose regimen . This formulation potential improve compliance . Current dose recommendation extend release formulation renal transplant 0.15 mg/kg/day administer daily morning . There specification appropriate dose obese patient whether use actual , ideal adjust weight . It advantageous understand pharmacokinetics medication obese determine appropriate dose regimen . In study , obese patient randomize receive tacrolimus extend release 0.15 mg/kg/day base either ideal body weight ( IBW ) adjust body weight ( aBW ) .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . The subject recipient live donor decease donor kidney transplant 2 . Subject &gt; 18 year age 3 . BMI≥30 POD 0 1 . Multiorgan transplant 2 . Subjects take tacrolimus pretransplant ( i.e . positive crossmatch transplant retransplants ) 3 . Patients undergo simultaneous sleeve gastrectomy time transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Transplant</keyword>
</DOC>